Volatile versus Total Intravenous Anesthesia for Coronary Artery Bypass Graft Surgery: Analysis of 1586 MYRIAD Trial Patients Managed with the Same Perioperative Protocol.

Autor:	Lomivorotov V; Department of Anesthesiology and Intensive Care, E. Meshalkin National Medical Research Center, 630055 Novosibirsk, Russia.; Department of Anesthesiology anf Intensive Care, Novosibirsk State University, 630090 Novosibirsk, Russia., Ruzankin PS; Sobolev Institute of Mathematics, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.; Department of Mathematics and Mechanics, Novosibirsk State University, 630090 Novosibirsk, Russia., Lembo R; Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy., Tarasenko AS; Sobolev Institute of Mathematics, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.; Department of Mathematics and Mechanics, Novosibirsk State University, 630090 Novosibirsk, Russia., Chernyavskiy A; Department of Anesthesiology and Intensive Care, E. Meshalkin National Medical Research Center, 630055 Novosibirsk, Russia., Crivellari M; Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy., Monaco F; Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy., Ruggeri L; Instituto Di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy., Pieri M; Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy., Lomivorotova L; Department of Anesthesiology and Intensive Care, E. Meshalkin National Medical Research Center, 630055 Novosibirsk, Russia., Belletti A; Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Jazyk:	angličtina
Zdroj:	Reviews in cardiovascular medicine [Rev Cardiovasc Med] 2022 Jul 21; Vol. 23 (8), pp. 265. Date of Electronic Publication: 2022 Jul 21 (Print Publication: 2022).
DOI:	10.31083/j.rcm2308265
Abstrakt:	Background: This study investigated the influence of volatile anesthesia (VA) on major complications and mortality in patients undergoing coronary artery bypass graft surgery (CABG). Methods: This post-hoc analysis included 1586 patients from the MYRIAD trial managed using the same perioperative protocol at a single institution. Patients were randomized to receive either volatile anesthesia (sevoflurane, isoflurane, or desflurane) or total intravenous anesthesia (TIVA). The assessed study outcomes were the rate of complications, including: myocardial infarction, stroke, acute kidney injury, prolonged ventilation ( > 24 h), receipt of high-dose inotropic support (inotropic score > 10), and need for mechanical circulatory support. The duration of intensive care unit (ICU) stay, length of hospitalization, hospital readmission during follow-up, 30-days and 1-year mortality were also analyzed. Results: 1586 patients were enrolled between September 2014-September 2017 and randomly assigned to the volatile anesthesia group (n = 794) and the TIVA group (n = 792). The median patient age was 63 years, with a median ejection fraction of 60%. There were no significant differences in the rates of major complications, duration of ICU stay, and hospitalization between the groups. The median total dose of fentanyl was 12.0 mcg/kg in volatile group and 14.4 mcg/kg in TIVA group ( p < 0.001). One-year mortality rates were 2.5% (n = 20) and 3.2% (n = 25) in the volatile and TIVA groups, respectively. Two patients were lost at the 30-day and 1-year follow-ups in the volatile group compared to four patients in TIVA group. Regression analysis showed that cardiopulmonary bypass (CPB) duration, fentanyl dose, and baseline serum creatinine level were associated with 30-days mortality, while ejection fraction was associated with 1-year mortality. Conclusions: The use of VA in patients undergoing CABG did not result in a reduction in major complications or mortality compared with TIVA. A higher dose of fentanyl was used in the TIVA group and was associated with an increase in the 30-days mortality. These findings warrant further investigation. Clinical Trial Registration: ClinicalTrials.gov (NCT02105610). Competing Interests: The authors declare no conflict of interest. Vladimir Lomivorotov is serving as one of the guest editors of this journal. We declare that Vladimir Lomivorotov had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Krishnaswami Vijayaraghavan. (Copyright: © 2022 The Author(s). Published by IMR Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu